Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 févr. 2015 08h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital

MALVERN, Pa., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post...
02 févr. 2015 16h22 HE | Source: Societal CDMO, Inc.

Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference

MALVERN, Pa., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post...
10 nov. 2014 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Reports Third Quarter 2014 Financial Results

MALVERN, Pa., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
29 oct. 2014 16h05 HE | Source: Societal CDMO, Inc.

Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

MALVERN, Pa., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
08 sept. 2014 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma to Present at the 2014 Aegis Healthcare & Technology Conference

MALVERN, Pa., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
04 sept. 2014 16h51 HE | Source: Societal CDMO, Inc.

Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN

Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1 Trial not expected to reach statistical significance as single agent on Post Op Day 0...
12 août 2014 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Reports Second Quarter 2014 Financial Results

MALVERN, Pa., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
30 juin 2014 07h00 HE | Source: Societal CDMO, Inc.

Recro Pharma Added to Russell Microcap(R) Index

MALVERN, Pa., June 30, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
17 juin 2014 07h30 HE | Source: Societal CDMO, Inc.

Recro Pharma Announces Dosing of First Patient in Phase IIb Clinical Trial of Dex-IN for Treatment of Acute Pain Following Surgery

MALVERN, Pa., June 17, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
12 mai 2014 07h30 HE | Source: Societal CDMO, Inc.

Recro Pharma Reports First Quarter 2014 Financial Results

MALVERN, Pa., May 12, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...

Page précédente